Ann: Appendix 4D and Half Year Accounts, page-2

Imo dont ignore the below considering the uptick in gross sales as per appendix 4D released today. The selling and buying volume on market over the last few months that continue to see a share price decline with non-material selling and buying volumes. BXN share trading is illiquid and bears no meaning on the bright prospects of BXN. In addition the directors keep repeating their buys on market. Note 71% of the register is held by the top 20 shareholders. No notice has been lodged with the ASX over a significant period of time indicating any of these holders have sold. BXN has always been a longer term investment however that longer investment term imo is on the cusp of coming to fruition.

Extract from release today....

The Company now has direct selling licenses in Malaysia and Indonesia and is progressing with applications for direct selling licenses in other key Asian countries. The license in Indonesia was acquired with our recent acquisition of a 95% interest in P.T. Gamata Utama (PTG) an Indonesian Direct Selling company. The effective date was September 2018, however the agreement provided that revenue for Bioxyne’s account would only be effective from 1 January 2019. As such, no revenue was recognised in the reported half year. PTG has held a direct sales license in Indonesia since May 2015 and has 2,500 active members. The company distributes an existing range of health products and supplements. Bioxyne sees this as a key geographical expansion with a growing middle class in a population of 267 million in Indonesia.